Salvage outcomes in patients with first relapse after fludarabine, cyclophosphamide, and rituximab for chronic lymphocytic leukemia: the French intergroup experience

American Journal of Hematology
Luc-Matthieu ForneckerLoic Ysebaert

Abstract

The optimal management of patients with relapsed chronic lymphocytic leukemia (CLL) is dictated by the type of prior therapy, duration of prior response, presence of genomic aberrations, age, and comorbidities. The patterns of relapses and the clinical outcomes of second-line options after fludarabine-cyclophosphamide-rituximab (FCR) is given as a frontline treatment are currently unknown. In this retrospective and non-randomized study, we report the outcomes of 132 patients from databases of 14 French CLL study group centers who needed a second-line treatment after FCR frontline. Bendamustine + rituximab (BR) was the most frequently used second-line regimen, followed by alemtuzumab-based regimens, R-CHOP, and FCR. Median progression-free survival (PFS) was 18 months after BR with a median overall survival (OS) not reached. We also found that response durations of < 36 months and the presence of del(17p) are critical factors that contribute to poor overall survival. BR appears to be an effective salvage regimen in our series, both in terms of progression-free and overall survival. Patients who relapsed less than 36 months after FCR have a poor outcome, not significantly different in this study from patients with early relapses ...Continue Reading

References

Nov 17, 2006·Leukemia·P DregerUNKNOWN Chronic Leukemia Working Party of the EBMT
Aug 17, 2011·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·Kirsten FischerClemens-Martin Wendtner
Oct 20, 2011·Annals of Oncology : Official Journal of the European Society for Medical Oncology·B EichhorstUNKNOWN ESMO Guidelines Working Group
Jan 24, 2014·The New England Journal of Medicine·Richard R FurmanSusan M O'Brien
Jun 3, 2014·The New England Journal of Medicine·John C ByrdUNKNOWN RESONATE Investigators

❮ Previous
Next ❯

Citations

Dec 8, 2015·The New England Journal of Medicine·Andrew W RobertsJohn F Seymour
Jun 30, 2015·Bulletin du cancer·Catherine Thieblemont
Jun 14, 2016·British Journal of Haematology·David J M Routledge, Adrian J C Bloor
Nov 4, 2017·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·Stephen Opat, Eliza A Hawkes
Jul 17, 2018·British Journal of Haematology·Anna H SchuhPeter Hillmen
Feb 6, 2017·International Journal of Hematology·Yoshiaki OgawaUNKNOWN Japanese Bendamustine CLL Study Group
Jun 20, 2020·Expert Opinion on Investigational Drugs·Fortunato MorabitoManlio Ferrarini
Oct 23, 2020·Annals of Oncology : Official Journal of the European Society for Medical Oncology·B EichhorstUNKNOWN ESMO Guidelines Committee. Electronic address: clinicalguidelines@esmo.org

❮ Previous
Next ❯

Related Concepts

Related Feeds

B-Cell Leukemia (Keystone)

B-cell leukemia includes various types of lymphoid leukemia that affect B cells. Here is the latest research on B-cell leukemia.